

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit 1617

1617 \$
JFW

Re Patent Application of

Richard B. Mazess et al

Application No. 09/995,911

Confirmation No.: 4126

Filed: November 28, 2001

Examiner: Theodore Criares

TREATMENT OF HYPERPROLIFERATIVE
DISEASES USING ACTIVE VITAMIN D
ANALOGUES

I, Sally J. Sorensen, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Signature

Sally Sorensen

Date of Signature

April 13, 2005

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §1.97(c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08B. Copies of the references are enclosed. Citation of these references is respectfully requested.

Also enclosed is a check in payment of the \$180.00 fee required under 37 CFR §1.17(p). Please charge or credit Deposit Account No. 50-0842 with any shortage or overpayment of the required fee.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

04/18/2005 MAHNE1 00000035 09995911

01 FC:1806


180.00 DP

Respectfully submitted,

Jeffrey D. Peterson
Jeffrey D. Peterson
Reg. No. 49,038

File No. 17620-9335

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
(608) 257-3501



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/995,911
				Filing Date	November 28, 2001
				First Named Inventor	Richard B. Mazess
				Group Art Unit	1617
				Examiner Name	Theodore Criares
Sheet	1	of	1	Attorney Docket Number	017620-9335

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Beer et al., "Rationale for the Development and Current Status of Calcitriol in Androgen-Independent Prostate Cancer," <i>World. J. Urol.</i> , (2004) 23:28-32.
		Beer et al., "Randomized Study of High-Dose Pulse Calcitriol or Placebo Prior to Radical Prostatectomy," <i>Cancer Epidemiology</i> , (2004) 13:12:2225-2232.
		Beer et al., "High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer," <i>Amer. J. Clinical Oncology</i> , (2004) 27:5:535-541.
		Beer et al., "Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients at Least 70 Years of Age Compared with Patients Younger than 70 Years," <i>Clinical Prostate Cancer</i> , (2003) 167-172.
		Beer et al., "Calcitriol in Cancer Treatment: From the Lab to the Clinic," <i>Molecular Cancer Therapeutics</i> , (2004) 3:3:373-381.
		Beer et al., "Quality of Life and Pain Relief During Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma," <i>Cancer</i> , (2004) 758-763.
		Beer T.M., "Development of Weekly High-Dose Calcitriol Based Therapy for Prostate Cancer," <i>Urologic Oncology</i> , (2003) 21:399-405.
		Beer et al., "Docetaxel (Taxotere) in the Treatment of Prostate Cancer," <i>Future Drugs Ltd.</i> , (2003) 3:3:261-268.
		Beer et al., "High-Dose Weekly Oral Calcitriol in Patients with a Rising PSA After Prostatectomy or Radiation for Prostate Carcinoma," <i>Cancer</i> , (2003) 97:5:1217-1224.
		Beer et al., "Phase II Study of Weekly Docetaxel in Symptomatic Androgen-Independent Prostate Cancer," <i>Annals of Oncology</i> , (2001) 12:1273-1279.
		Beer et al., "A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies," <i>Cancer</i> , (2001) 91:12:2431-2439.

U:AB0253084.1

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.